Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design

Robin Kate Kelley, Jennifer W Oliver, Saswati Hazra, Fawzi Benzaghou, Thomas Yau, Ann-Lii Cheng, Lorenza Rimassa

Research output: Contribution to journalArticlepeer-review

Abstract

Cabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppressive microenvironment. Cabozantinib is approved as single-agent therapy for patients with advanced hepatocellular carcinoma who received prior sorafenib. Owing to its antitumor and immunomodulatory properties, cabozantinib is being developed in combination with immune checkpoint inhibitors. Early studies of these combinations have shown promising antitumor activity and tolerability in patients with solid tumors. Here, we describe the rationale and design of COSMIC-312, a Phase III study evaluating the safety and efficacy of cabozantinib in combination with atezolizumab (anti-PD-L1 monoclonal antibody) versus sorafenib for treatment-naive patients with advanced hepatocellular carcinoma. ClinicalTrial.gov Registration: NCT03755791.

Original languageEnglish
Pages (from-to)1525-1536
Number of pages12
JournalFuture oncology (London, England)
Volume16
Issue number21
DOIs
Publication statusPublished - Jul 2020

Fingerprint Dive into the research topics of 'Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design'. Together they form a unique fingerprint.

Cite this